Biotechnology — Overview
Biotechnology is the use of living organisms, cells, or biological systems to develop products and technologies for human benefit. It spans agriculture, health, industry, and environment.
Colour Classification of Biotechnology
| Colour | Domain | Examples |
|---|---|---|
| Red | Medical / Pharmaceutical | Gene therapy, vaccines, diagnostics, biopharmaceuticals, stem cells |
| Green | Agricultural | GM crops, biopesticides, biofertilisers, molecular breeding, biofortification |
| White | Industrial | Biofuels, enzymes, bioplastics, fermentation technology |
| Blue | Marine / Aquatic | Marine-derived pharmaceuticals, aquaculture biotechnology |
| Yellow | Food / Nutrition | Food processing, nutraceuticals, biofortification |
| Grey | Environmental | Bioremediation, waste treatment, biodegradation |
India's Bioeconomy & BioE3 Policy
India's Bioeconomy Growth
| Indicator | Value |
|---|---|
| Bioeconomy size (2025) | $195.3 billion (~5% of GDP) |
| Growth trajectory | $10B (2014) → $80B (2020) → $165.7B (2024) → $195.3B (2025) |
| Growth rate (2025) | 18% YoY |
| Growth trajectory | $10B (2014) → $70B (2020) → $130B (2023) → $165.75B (2024) → $195.3B (2025) |
| Registered biotech startups | 11,855 (1,780 new in 2025); India 3rd largest biotech hub in Asia-Pacific, 12th globally |
| Bio-incubators | 95 BIRAC-supported centres |
| Key segments | BioPharma ($64.5B), BioIndustrial ($90.2B), BioAgri, BioServices |
| Vision 2047 | $1 trillion bioeconomy goal (Amrit Kaal) |
BioE3 Policy (2024)
| Feature | Detail |
|---|---|
| Approved | Cabinet approval on 24 August 2024 |
| Full form | Biotechnology for Economy, Environment and Employment |
| Goal | $300 billion bioeconomy by 2030; high-performance biomanufacturing |
| Focus areas | Bio-based chemicals; smart proteins; precision biotherapeutics; climate-resilient agriculture; carbon capture; marine and space research |
| Infrastructure | Biomanufacturing & Bio-AI hubs; Biofoundries across India |
BioE3 significance: Aligns with India's Net Zero and LiFE goals. Promotes circular bioeconomy and green growth, with job creation in tier-II/III cities through biomanufacturing hubs.
Genetic Engineering — Key Concepts
| Term | Meaning |
|---|---|
| GMO | Genetically Modified Organism — has DNA altered using genetic engineering (transgenic: gene from different species) |
| Genome editing | Precise modification of an organism's own DNA without introducing foreign genes (e.g., CRISPR) |
| Transgenic | Contains gene(s) from another species (e.g., Bt cotton has gene from Bacillus thuringiensis) |
| Cisgenic | Contains gene from a sexually compatible species — no foreign species involved |
| Gene silencing (RNAi) | Switching off a specific gene without removing it |
| CRISPR-Cas9 | Molecular "scissors" that cut DNA at precise locations; enables cheap, fast, accurate gene editing |
Prelims Trap: GMOs and genome-edited organisms are NOT the same. GMOs contain foreign DNA (transgenic). Genome-edited organisms have their own DNA modified — no foreign genetic material is introduced. India's 2022 guidelines treat genome-edited plants (SDN-1 and SDN-2 categories) differently from GMOs, with a lighter regulatory pathway.
CRISPR-Cas9
How It Works
| Feature | Detail |
|---|---|
| Full form | Clustered Regularly Interspaced Short Palindromic Repeats |
| Discovered by | Jennifer Doudna & Emmanuelle Charpentier — Nobel Prize in Chemistry, 2020 |
| Mechanism | Guide RNA directs Cas9 enzyme to target DNA → Cas9 cuts the DNA → cell's repair mechanism edits it |
| Advantages | Precise, cheap, fast, versatile (works in plants, animals, humans) |
| Limitations | Off-target effects, mosaicism, ethical concerns in human germline editing |
CRISPR Applications
| Domain | Application | Example |
|---|---|---|
| Medicine | Gene therapy for genetic disorders | Casgevy — first CRISPR therapy, US FDA approved 2023 (sickle cell disease) |
| India (Medicine) | Indigenous CRISPR gene therapy | BIRSA 101 — CRISPR therapy for Sickle Cell Disease by CSIR-IGIB (with Serum Institute) |
| Agriculture | Drought/salinity tolerance | IARI's Pusa Rice DST1 (drought-salinity tolerant, SDN-1 edit, approved 2025) |
| Diagnostics | Rapid pathogen detection | FELUDA test (IGIB Delhi) — paper-based CRISPR COVID-19 test; 96% sensitivity, 98% specificity |
| Industrial | Bio-based chemicals, biofuel feedstock | Engineering microbes for biofuel production |
India's CRISPR institutions: National Centre for Genome Editing & Training (NGETC) at Mohali; regulatory framework under National Guidelines for Gene Therapy (2019), CDSCO, NDCT Rules 2019.
GM Crops in India
Bt Cotton — India's Only Approved GM Crop
| Feature | Detail |
|---|---|
| Approved | 2002 (Bollgard I); Bollgard II (two Bt genes: cry1Ac + cry2Ab) approved 2006 |
| Technology | Contains cry1Ac gene (and later cry2Ab) from Bacillus thuringiensis → produces Bt toxin → kills bollworm larvae |
| Adoption | ~95% of India's cotton area is now Bt cotton |
| Impact | Cotton production tripled (13.6 million bales in 2002 → 35.4 million bales by 2014); India became world's largest cotton producer |
| Controversy | Pink bollworm resistance emerged (Gujarat, Maharashtra); seed monopoly concerns (Monsanto/Bayer); farmer suicide debate (correlation, not proven causation) |
For Mains: The Bt cotton story is nuanced. Initial benefits were real — tripled yields, ~70% reduction in pesticide use against bollworm. But pink bollworm resistance development and dependence on proprietary seeds created new vulnerabilities. Use as a case study of technology adoption — benefits vs risks of monoculture and corporate dependency.
Bt Brinjal — Moratorium Since 2010
| Feature | Detail |
|---|---|
| Developed by | Mahyco (Maharashtra Hybrid Seeds Company), Jalna |
| GEAC approval | October 14, 2009 — cleared for commercial cultivation |
| Moratorium | February 9, 2010 — Environment Minister Jairam Ramesh imposed indefinite moratorium |
| Reason | No overriding food security urgency; opposition from 9 state governments; widespread public concern; brinjal is India's centre of origin (gene flow to wild relatives risk) |
| Current status | Moratorium continues in India; however, Bangladesh has successfully cultivated Bt Brinjal commercially since 2014; 2020 — GEAC allowed confined field trials of indigenous Bt Brinjal varieties in 8 states |
GM Mustard (DMH-11) — Ongoing Controversy
| Feature | Detail |
|---|---|
| Developed by | Delhi University (Prof. Deepak Pental's team) |
| Technology | Hybrid mustard using barnase-barstar gene system from Bacillus amyloliquefaciens |
| Yield advantage | ~28% higher than national check variety |
| GEAC approval | October 2022 — approved for environmental release |
| Supreme Court | Split verdict (2024) — Justice Nagarathna invalidated; Justice Karol upheld. Referred to larger bench |
| Context | India imports 55–60% of edible oil; DMH-11 could boost domestic production |
Why it matters: DMH-11 could be India's second GM crop after 22 years. The debate combines science (safety), politics (anti-GM activism), economics (edible oil import burden), and federalism (states like Rajasthan oppose). A classic multi-dimensional Mains question.
Genome-Edited Crops — India's New Pathway (2025)
India approved its first genome-edited crop varieties in 2025 — NOT GMOs (no foreign DNA; SDN-1 category edit):
| Variety | Developed by | Feature |
|---|---|---|
| Pusa Rice DST1 | IARI, New Delhi | Drought and salinity tolerance |
| DRR Dhan 100 | IIRR, Hyderabad | Improved grain quality and yield |
India's 2022 genome editing guidelines exempt SDN-1 and SDN-2 edits from the full GMO regulatory process — creating a faster innovation pathway for crops that only modify the plant's own DNA.
Common Prelims Mistake: Bt Cotton is the ONLY commercially approved GM crop in India (since 2002). Bt Brinjal was approved but placed under moratorium (2010). GM Mustard got GEAC approval (2022) but is in legal limbo (SC 2024). Genome-edited crops (Pusa Rice DST1, DRR Dhan 100) are NOT GMOs — different regulatory category.
Regulatory Framework for GMOs in India
Key Laws
| Legislation | Role |
|---|---|
| Environment Protection Act, 1986 | Umbrella law for GMO regulation |
| Rules for Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/GMOs, 1989 | Primary biosafety regulatory framework; notified under EPA 1986 |
| Food Safety and Standards Act, 2006 | Regulates GM food imports and labelling |
| Biological Diversity Act, 2002 | Governs access to genetic resources |
International: Cartagena Protocol on Biosafety
| Feature | Detail |
|---|---|
| Nature | Supplementary agreement to the CBD — focused on safe transfer/handling/use of Living Modified Organisms (LMOs) |
| Adopted | January 29, 2000 (Montreal); In force: September 11, 2003 |
| India | India is a Party |
| Key principle | Advance Informed Agreement (AIA): Exporting country must notify importing country and get consent before first transboundary movement of an LMO for release into the environment |
| Precautionary principle | Uncertainty about risks does not preclude taking preventive measures |
| Biosafety Clearing House (BCH) | Online platform for exchanging biosafety information globally |
India's Rules 1989 under EPA 1986 are broadly aligned with the Cartagena Protocol's requirements for risk assessment and information exchange.
Key Biosafety Risks
| Risk | Explanation |
|---|---|
| Horizontal gene transfer | Transgenes may transfer to soil bacteria or wild plant relatives, creating ecological changes |
| Biodiversity impact | Herbicide-tolerant GM crops may lead to monocultures, reducing agro-biodiversity |
| Allergenicity | Foreign proteins in GM food could trigger allergic reactions |
| Resistance development | Insects/weeds can develop resistance to Bt toxin or herbicide → "super-pests" and "super-weeds" |
| Cross-pollination | GM pollen can contaminate non-GM and organic crops in neighbouring fields |
Six-Tier Regulatory Structure
| Body | Level | Role |
|---|---|---|
| RCGM (Review Committee on Genetic Manipulation) | DBT | Reviews research proposals involving GMOs |
| GEAC (Genetic Engineering Appraisal Committee) | MoEFCC | Apex body — approves environmental release of GMOs; renamed from "Approval" to "Appraisal" in 2010 |
| IBSC (Institutional Biosafety Committee) | Institution | Monitors recombinant DNA research at each institution |
| SBCC (State Biotechnology Coordination Committee) | State | Monitors GMO use at state level |
| DLC (District Level Committee) | District | Monitors field trials at district level |
| RDAC (Recombinant DNA Advisory Committee) | DBT | Advises on recombinant DNA research policy |
Prelims Fact: GEAC (under MoEFCC) is the apex approval body. RCGM (under DBT) handles research-stage approvals. Don't confuse the two. Agriculture is a State subject, but GM crop regulation is under EPA 1986 (Union law) — creating Centre-state tension.
Genome Editing Guidelines — SDN Categories (2022)
| Category | Description | Regulatory Pathway |
|---|---|---|
| SDN-1 | Small deletions/insertions; no foreign DNA | Exempt from GMO regulations — treated like conventional breeding |
| SDN-2 | Small changes using a DNA template from same/related species | Lighter regulation than GMOs |
| SDN-3 | Insertion of foreign DNA using CRISPR | Regulated as full GMO (GEAC process required) |
Medical Biotechnology
Gene Therapy
| Aspect | Detail |
|---|---|
| CRISPR-Cas9 | Enables precise modification of DNA sequences — see CRISPR section above |
| India's first CRISPR therapy | BIRSA 101 — indigenous CRISPR-based gene therapy for Sickle Cell Disease, developed by CSIR-IGIB; partner: Serum Institute of India |
| CRISPR Diagnostic | Tata CRISPR test (FELUDA) — India's first CRISPR-based COVID-19 diagnostic; approved by DCGI |
| NGETC | National Centre for Genome Editing & Training — Mohali, Punjab |
Key Indian Vaccine Contributions
| Vaccine | Developer | Type | Significance |
|---|---|---|---|
| Covaxin (BBV152) | Bharat Biotech + ICMR-NIV Pune | Whole Virion Inactivated | India's first fully indigenous COVID-19 vaccine; 81% efficacy in Phase 3 |
| Covishield | Serum Institute of India (SII) | Recombinant Adenovirus Vector (AstraZeneca-Oxford) | 70.42% efficacy; SII capacity ~250–275 million doses/month |
| Rotavac | Bharat Biotech | Live attenuated oral | India's indigenous rotavirus vaccine; WHO prequalified |
| CERVAVAC | Serum Institute of India | Quadrivalent HPV | India's first indigenous cervical cancer vaccine |
| ZyCoV-D | Zydus Cadila | DNA plasmid | World's first DNA plasmid COVID-19 vaccine |
Genome Sequencing Projects
| Project | Lead Agency | Details |
|---|---|---|
| IndiGen | CSIR (IGIB Delhi + CCMB Hyderabad) | WGS of 1,029 Indians; identified 55.9 million SNVs; 32.23% unique to India |
| GenomeIndia | Department of Biotechnology (DBT) | WGS of 10,074 individuals from 83 distinct populations (99 communities); data opened by PM Modi on 9 January 2025; 135 million+ genetic variations identified |
Why Genome India matters: Global genomic databases are dominated by European-ancestry data. Indians are genetically distinct and diverse. Without an Indian reference genome, precision medicine cannot work for India's population.
Biotech in Agriculture — Beyond GM Crops
Key Technologies
| Technology | Application | Status in India |
|---|---|---|
| Biopesticides | Microbial agents (Trichoderma, Beauveria, Bt spray) for pest control | Widely used; growing market |
| Biofertilisers | Nitrogen-fixing bacteria (Rhizobium), phosphate solubilisers | Promoted under Soil Health Card scheme |
| Tissue culture | Mass propagation of disease-free planting material | Used for banana, potato, sugarcane |
| Marker-assisted selection (MAS) | Using DNA markers to select desirable traits without genetic modification | Used in rice drought-tolerant varieties |
| Biofortification | Enhancing nutrient content through conventional breeding + biotech | 71+ ICAR varieties released |
| Precision agriculture | GPS, IoT sensors, drones, AI for data-driven farming | Digital Agriculture Mission; Kisan Drone initiative |
| Vertical farming | Indoor multi-layer crop production using hydroponics/LED lighting | Startups in Mumbai, Bangalore, Delhi NCR |
Biofortification — Key Indian Varieties
ICAR has released 71+ biofortified varieties across multiple crops:
| Crop | Variety | Nutrient Enriched |
|---|---|---|
| Wheat | Pusa Tejas (HI 8759) | High protein (12%), iron (42 ppm), zinc (43 ppm) |
| Rice | CR Dhan 315 | High zinc |
| Maize | Pusa Vivek QPM9 Improved | High provitamin-A, lysine, tryptophan (Quality Protein Maize) |
| Pearl millet | Dhanashakti | High iron (70–75 mg/kg), zinc (35–40 mg/kg) |
| Sweet potato | Bhu Sona | High beta-carotene (provitamin-A) |
Golden Rice (engineered with beta-carotene genes) approved in Australia, New Zealand, Canada — NOT approved in India. Remains a GM crops debate topic.
India's Biotech Institutional Framework
Department of Biotechnology (DBT)
| Parameter | Detail |
|---|---|
| Established | 1986 — under Ministry of Science & Technology |
| Significance | India was among the first countries to have a dedicated government body for biotechnology |
| Functions | Funds R&D; promotes innovation; international collaborations; policy formulation |
| Focus Areas | Healthcare, food security, environmental sustainability, energy security |
BIRAC (Biotechnology Industry Research Assistance Council)
| Parameter | Detail |
|---|---|
| Type | Not-for-profit Section 8 Public Sector Enterprise under DBT |
| Role | Interface agency to strengthen emerging biotech enterprises; strategic research and innovation funding |
| Programmes | BIG (Biotechnology Ignition Grant), SPARSH, PACE, SEED Fund, CRS |
| Bio-incubators | 95 BIRAC-supported centres across India |
National Biopharma Mission (NBM/i3)
| Feature | Detail |
|---|---|
| Outlay | ₹1,500 crore (~$250 million); 50% co-funded by World Bank |
| Objective | Accelerate biopharmaceutical development — from discovery to clinical trials to commercialisation |
| Scale | 101 projects; 150+ organisations; 30 MSMEs supported |
| Focus | Indigenous vaccines, biosimilars, diagnostics, biotherapeutics |
India's Biopharmaceuticals — Global Position
| Category | India's Position |
|---|---|
| Vaccines | Largest global vaccine producer by volume; Serum Institute of India = world's largest vaccine manufacturer (~1.5 billion doses/year) |
| Generic formulations | ~20% of global generic medicine volume; largest supplier to WHO prequalified procurement |
| Biosimilars | 100+ approved biosimilars in India; rapidly growing segment |
| Insulin | Major producer — Biocon, Lupin, Wockhardt |
One Health Approach
| Aspect | Detail |
|---|---|
| Concept | Integrated approach recognising the interconnection between human health, animal health, and the environment |
| Relevance | ~75% of emerging infectious diseases are zoonotic in origin (COVID-19, SARS, Nipah, Ebola) |
| India's Adoption | NAP-AMR (2017) adopted One Health framework; inter-ministerial coordination between MoHFW, MoAHD, MoEFCC |
| Key Focus Areas | Zoonotic diseases, food safety, antibiotic resistance, environmental health |
| Research Initiative | ICMR-DBT-ICAR One Health Consortium (2021) — collaborative surveillance and research network |
Exam Tip: For any UPSC answer on COVID-19, AMR, or avian flu, invoke the One Health framework. Key fact: ~75% of emerging infectious diseases are zoonotic. India's NAP-AMR (2017) explicitly adopted this approach. The institutional challenge is inter-ministerial coordination between MoHFW, MoAHD, and MoEFCC.
Antimicrobial Resistance (AMR)
| Parameter | Detail |
|---|---|
| NAP-AMR 1.0 | Launched 19 April 2017; aligned with WHO Global Action Plan on AMR |
| NAP-AMR 2.0 | Launched in 2024; updated strategy with human health, research, animal husbandry, and environment sectors |
| Global scale | ~1.27 million deaths/year (Lancet, 2022); could cause 10 million/year by 2050 |
| India's burden | Among world's highest antibiotic consumers; ~119,000 MDR/RR-TB cases/year |
| ESKAPE pathogens | Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter |
| Surveillance | ICMR's AMR Surveillance Network (AMRSN); data to WHO's GLASS system |
| Root causes | Over-the-counter antibiotics; irrational prescriptions; antibiotic overuse in agriculture/veterinary use |
Ethical and Social Dimensions
| Issue | Discussion Points |
|---|---|
| Food safety | Are GM foods safe? Scientific consensus: yes (approved varieties). Public perception differs |
| Farmer autonomy | GM seeds are often patented → farmers cannot save seeds → corporate dependency |
| Biodiversity risk | Gene flow from GM crops to wild relatives could create "superweeds" |
| Labelling | India requires GM food labelling but enforcement is weak |
| Gene editing ethics | Crops (widely accepted) → Animals (debated) → Human embryos (banned in most countries) |
| Access and equity | Will biotech benefits reach smallholders or only corporate farms? |
| Biopiracy | Exploitation of indigenous genetic resources without benefit-sharing |
Biopiracy Landmark Cases
Turmeric Patent (1995–1997):
- US Patent No. US5401504A granted to University of Mississippi Medical Centre (1995) for use of turmeric in wound healing
- CSIR challenged it, proving turmeric's wound-healing use was documented in ancient Ayurvedic texts — not novel
- USPTO revoked the patent in 1997 — one of the earliest successful biopiracy challenges
Neem Patent (1994–2005):
- European Patent Office (EPO) granted Patent EP436257 to W.R. Grace & Co. and USDA on a neem-based fungicide (1994)
- Dr. Vandana Shiva and activists filed opposition citing India's traditional neem use
- EPO revoked the patent in May 2000; appeal confirmed final revocation in 2005
Traditional Knowledge Digital Library (TKDL)
| Feature | Detail |
|---|---|
| Established | 2001 — joint initiative of CSIR and Ministry of AYUSH |
| Purpose | Document India's traditional medicinal knowledge in machine-readable format accessible to global patent offices |
| Content | ~0.9 million formulations from Ayurveda, Unani, Siddha, and Yoga texts |
| Languages | Available in English, French, German, Spanish, and Japanese |
| Access | Provided to patent examiners at USPTO, EPO, JPO, UKIPO, CIPO as prior art database |
| Impact | Cited in 200+ patent examination proceedings; prevented grant of patents on traditional Indian knowledge |
TKDL represents India's "defensive protection" strategy — documenting traditional knowledge as prior art to prevent others from patenting it, rather than patenting it (which may not meet novelty criteria).
Important for UPSC
Prelims Focus Areas
- Bt Cotton: only GM crop approved in India (2002); GEAC is apex body under MoEFCC (not MoA or DBT)
- Bt Brinjal moratorium: February 2010, Jairam Ramesh; moratorium continues
- GM Mustard (DMH-11): GEAC approved October 2022; SC split verdict 2024; legal limbo
- Genome-edited crops (2025): Pusa Rice DST1 + DRR Dhan 100 — NOT GMOs (SDN-1 category)
- CRISPR: Nobel Prize Chemistry 2020 — Doudna & Charpentier; FELUDA = Tata + CSIR-IGIB
- SDN-1/SDN-2/SDN-3 categories for genome editing
- DBT established 1986; BIRAC = PSE under DBT
- BioE3 Policy: Cabinet August 24, 2024; $195.3B bioeconomy (2025)
- NAP-AMR launched 2017; updated 2024; ESKAPE pathogens
- GenomeIndia: 10,074 individuals, 83 populations; IndiGen: 1,029 individuals
- Biofortified varieties: Pusa Tejas (wheat), Dhanashakti (pearl millet), CR Dhan 315 (rice)
- BIRSA 101: India's first indigenous CRISPR gene therapy (CSIR-IGIB + SII)
Mains Dimensions
| Dimension | Angle |
|---|---|
| Science & Tech (GS3) | CRISPR applications (agriculture + medicine); GM crop debate; genome sequencing for precision medicine; biofortification as nutrition solution |
| Governance (GS2) | Regulatory framework for GM crops — adequacy, Centre-state tensions; GEAC vs RCGM; gene therapy oversight |
| Economy (GS3) | India's bioeconomy ($195.3B, 2025); BioE3 Policy; pharma sector — "Pharmacy of the World"; biotech start-up ecosystem |
| Social Issues (GS1/GS2) | Health equity (UHC through PMJAY); tribal health and sickle cell disease (BIRSA 101) |
| Ethics (GS4) | Ethics of gene editing in humans; GM crop safety vs food security; clinical trial ethics; informed consent; biopiracy |
| Environment (GS3) | One Health approach; AMR and environment; biosafety concerns with GM organisms; gene drives for invasive species |
Interview Angles
- Should India allow GM food crops beyond Bt Cotton? What's the right balance between food security and biosafety?
- Gene editing: where should India draw the ethical line? Crops vs animals vs human germline?
- India's TKDL model — can traditional knowledge be effectively protected in the IP regime?
- Is India's bioeconomy growth ($195B) benefiting small farmers and rural populations?
- One Health: is India's institutional structure adequate for cross-sectoral health governance?
Vocabulary
Genome
- Pronunciation: /ˈdʒiː.nəʊm/
- Definition: The complete set of genetic material (DNA or, in some viruses, RNA) present in a cell or organism, containing all the information needed for that organism's development and function.
- Origin: Coined by German botanist Hans Winkler in 1920, as a blend of German Gen ("gene") and Chromosom ("chromosome").
CRISPR
- Pronunciation: /ˈkrɪs.pər/
- Definition: An acronym for Clustered Regularly Interspaced Short Palindromic Repeats, a gene-editing technology derived from a bacterial defence system that enables precise modification of DNA sequences in living organisms.
- Origin: The acronym was proposed by Francisco Mojica and Ruud Jansen in 2001; the gene-editing application using CRISPR-Cas9 was developed by Jennifer Doudna and Emmanuelle Charpentier (Nobel Prize in Chemistry, 2020).
Transgenic
- Pronunciation: /trænzˈdʒɛn.ɪk/
- Definition: Describing an organism whose genome has been altered by the introduction of one or more genes from a different species using genetic engineering techniques.
- Origin: From Latin trans- ("across") + Greek genos ("race, kind") + -ic; coined in the 1980s to describe organisms carrying foreign genetic material.
Biopesticide
- Pronunciation: /ˌbaɪoʊˈpɛstɪˌsaɪd/
- Definition: A pest-control agent derived from natural biological sources — such as bacteria, fungi, viruses, or plant extracts — used as an environmentally safer alternative to synthetic chemical pesticides.
- Origin: Compound of Greek bios ("life") + Latin pestis ("plague, pest") + -cide (from Latin caedere, "to kill").
Biofertiliser
- Pronunciation: /ˌbaɪoʊˈfɜːrtɪˌlaɪzər/
- Definition: A substance containing living micro-organisms — such as nitrogen-fixing bacteria (Rhizobium) or phosphate-solubilising fungi — that, when applied to seeds, plant surfaces, or soil, enhances nutrient availability and promotes plant growth.
- Origin: Contraction of biological fertiliser; bio- from Greek bios ("life").
Key Terms
Genetic Modification
- Pronunciation: /dʒəˈnɛt.ɪk ˌmɒd.ɪ.fɪˈkeɪ.ʃən/
- Definition: The deliberate alteration of an organism's DNA using laboratory techniques — including insertion of foreign genes (transgenic), deletion of existing genes, or site-specific modification using CRISPR-Cas9. The key regulatory distinction: traditional GM (foreign DNA, full GEAC process) vs genome editing SDN-1/SDN-2 (no foreign DNA, lighter regulation).
- Context: Bt cotton (cry1Ac gene) is India's only approved GM crop since 2002. Bt Brinjal was approved by GEAC October 2009 but placed under moratorium February 2010 (Jairam Ramesh). GM Mustard (DMH-11) received GEAC approval October 2022 but faces SC legal challenge (split verdict 2024). India's first genome-edited crops (Pusa Rice DST1, DRR Dhan 100) approved 2025 — SDN-1 category, no foreign DNA.
- UPSC Relevance: GS3 (Science & Technology). Know SDN-1/SDN-2/SDN-3 categories; GEAC under MoEFCC is apex GM approval body; RCGM under DBT handles research stage. Mains: GM crops debate, biopiracy (TKDL, Neem/Turmeric), Centre-state tensions, food security vs biosafety.
Bt Cotton
- Pronunciation: /ˌbiː ˈtiː ˈkɒtən/
- Definition: India's only approved GM crop (since 2002), containing the cry1Ac gene from Bacillus thuringiensis that produces insecticidal proteins toxic to bollworm larvae. Covers ~95% of India's cotton area; tripled cotton production by 2014. Controversies: pink bollworm resistance emerged; seed monopoly concerns (Monsanto/Bayer); farmer suicide debate (correlation only, not proven causation).
- UPSC Relevance: GS3. Prelims: approved 2002, only approved GM crop, GEAC under MoEFCC. Mains: Use as case study for technology adoption — initial success (tripled production, ~70% pesticide reduction) vs emerging challenges (resistance, dependency). Centre-state regulation tensions.
GM Crops Regulation
- Pronunciation: /ˌdʒiː ˈɛm krɒps ˌrɛɡjuˈleɪʃən/
- Definition: India's six-tier framework: IBSC (institution) → RCGM (DBT) → RDAC (DBT policy) → SBCC (state) → DLC (district) → GEAC (apex, MoEFCC). Primary law: GMO Rules 1989 under EPA 1986. GEAC renamed from "Approval" to "Appraisal" Committee in July 2010. SDN-1/SDN-2 genome-edited plants exempt from full GMO process per 2022 SOPs.
- UPSC Relevance: GS3 (Governance/Science). Know GEAC is under MoEFCC not DBT. Mains: Centre-state friction (agriculture = State subject; GM regulation = Union law), adequacy of India's regulatory framework, GM Mustard SC case 2024.
Stem Cell Therapy
- Pronunciation: /stɛm sɛl ˈθɛr.ə.pi/
- Definition: Regenerative medicine using stem cells to repair or replace diseased tissues. Types: embryonic stem cells (pluripotent), adult/somatic stem cells (multipotent), and induced pluripotent stem cells (iPSCs — adult cells reprogrammed by Shinya Yamanaka, Nobel 2012). India's regulatory framework: ICMR-DBT National Guidelines for Stem Cell Research (1st 2007, revised 2017). Reproductive cloning prohibited; therapeutic cloning permitted under oversight.
- UPSC Relevance: GS3. Prelims: types of stem cells; iPSC Nobel 2012 (Yamanaka + Gurdon). Mains: ethical concerns (embryonic SC research involves embryo destruction), India's regulatory framework, therapeutic applications (bone marrow transplants, potential for Parkinson's, diabetes).
Current Affairs Connect
| Resource | Link |
|---|---|
| Science & Tech News | Ujiyari — Science & Tech News |
| Editorials | Ujiyari — Editorials |
Sources: pib.gov.in, dbtindia.gov.in, birac.nic.in, mohfw.gov.in, nhm.gov.in, nha.gov.in, moefcc.gov.in, ncdc.mohfw.gov.in, india.gov.in, Lancet 2022 (AMR data), ICAR biofortification data.
BharatNotes